Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{178766,
        author = {Kajal M. Thakur and C.K. Gadewar},
        title = {Lariocidin A: A Promising Frontier in the Battle Against Antimicrobial Resistance — A Comprehensive Review},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {12},
        pages = {5098-5103},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=178766},
        abstract = {The scientific community is being urged to investigate new therapeutic agents since the growing problem of antimicrobial resistance (AMR) has made many traditional medicines ineffective. Lariocidin A, a ribosomally produced and post-translationally modified peptide (RiPP), is one of the more recent discoveries. It is a powerful antibiotic with a distinct mode of action that avoids common resistance mechanisms. This thorough analysis explores Lariocidin A's biosynthesis, structure, antimicrobial spectrum, and mode of action, emphasizing its effectiveness against Gram-positive bacteria, including strains of Staphylococcus aureus and Enterococcus faecalis that are resistant to many drugs. The review also looks at pharmacological characteristics that support its therapeutic promise, preclinical results, and synergistic potential with current antibiotics. Also, we investigate how Lariocidin A circumvents established resistance mechanisms such efflux pumps and target site alterations. This review highlights Lariocidin A's strategic importance in contemporary antibiotic development by contrasting it with other newly discovered antimicrobial peptides. Lariocidin A stands out as a strong option for next-generation antibacterial therapy, providing fresh hope in the fight against AMR as global health systems prepare for a post-antibiotic age.},
        keywords = {Lariocidin A, antimicrobial resistance, novel antibiotics, RiPPs, drug-resistant pathogens, antibacterial peptides, mechanism of action, multidrug resistance, next-generation antibiotics, peptide antibiotics, Gram-positive bacteria, resistance evasion.},
        month = {May},
        }